Article Text

Download PDFPDF

Simvastatin reduced mortality and vascular events

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

 QUESTION: In patients with a high 5 year risk of death, does simvastatin reduce mortality and vascular events?


Randomised (allocation concealed*), blinded (participants, clinicians, data collectors, and outcome assessors),* placebo controlled trial with mean follow up of 5 years.


69 UK hospitals.


20 536 patients who were 40–80 years of age (28% were ≥70 y of age, 75% men); had nonfasting total cholesterol levels ≥3.5 mmol/l; and had a substantial 5 year risk of death because of a history of coronary heart disease (CHD), occlusive disease of noncoronary arteries, or diabetes mellitus or a history of treated hypertension (in men ≥65 y of age). Exclusion criteria included a clear indication for statin therapy according to the patient‘s doctor; abnormal liver or renal function; muscle problems; concurrent treatment with cyclosporin, fibrates, or high dose niacin; potential for pregnancy; and serious medical conditions. Follow up was 99.7%.


Run in treatment consisted of 4 weeks of placebo and 4–6 weeks of simvastatin, …

View Full Text